In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Value-Based Health Care Is Here To Stay

Necessity Is The Mother Of Invention

Executive Summary

COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.

You may also be interested in...



Technology’s place in value-based healthcare: HETTExpo 2012

Smart use of healthcare technology improves care delivery, saves time, increases productivity and can improve staff morale. At some point in the usage cycle, savings will start to be made, although when this happens – and whether it should be the prime reason for the adoption of IT-based healthcare delivery solutions – is open to debate. What is clear is that a modern approach is vital if state-provided healthcare, as we know it, is to remain sustainable in the long term. The private and public sectors both have key roles to play, says Ashley Yeo, at the second annual HETTExpo

Time is Ripe For Large-Scale German Hospital Reform – Health Ministry

DRGs are not doing what they were conceived to, ambulatory care needs more support and health care delivery across the country must be unburdened from bureaucracy, health minister Karl Lauterbach told the German hospital congress meeting during Medica 2022.

‘A Fuse Burning At Both Ends’: German Near-Term Market Outlook For Medtech Industry

Later market launch of innovations and a hit on EBITDA are simultaneously affecting medtech companies in Germany and central Europe as they strive to keep quality uppermost while battling the most frustrating confluence of negative effects on business than most companies have ever seen.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV124604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel